DOCSLIB.ORG

Molecular Breast Imaging Mammography: the Probllem

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Molecular Breast Imaging Mammography: The Probllem Michael O ’Connor, PhD Department of Radiology Mayo Clinic Rochester, MN This work has been funded in part by the following: National Institute of Health Dept. of Defense Breast cancer and Cancer clearly visible Cancer would be occult Susan G Komen Foundation tumors appear white in non-dense breast in dense breast on mammogram Mayo Foundation Sensitivity Sensitivity Friends for an Earlier Breast Cancer Test 80%-90% 40%-70% Breast Cancer Sensiitiiviity of MMG, US, and MRI Comparatiive Rellatiive Riisks iin Women at Increased Riisk Subjjectts Sensiittiiviitty Sensiittiiviitty Sensiittiiviitty Riisk factor Rellatiive riisk Autthorr//yearr Counttrry ((no..)) MMG ((%)) US ((%)) MRII ((%)) BRCA muttattiion 20 Kuhll ,, 2000 Gerrmany 192 33 33 100 Lobullar carciinoma iin siittu 8-10 Dense breastt parenchyma 4-6 Warrnerr,, 2004 Canada 236 36 33 77 Personal history of breast cancer 3-4 Personal history of breast cancer 3-4 Krriiege ,, 2004 Nettherrllands 1,,909 40 NA 71 Famiilly hiisttory ((1 ° rellattiive)) 2..1 Kuhll ,, 2005 Gerrmany 529 33 40 91 Posttmenopausall obesiitty 1..5 Prempro ((WHII)) 1..26 Leach 2005 U..K.. 649 40 NA 77 Sarrdanellllii ,, 2006 IIttally 3571 40 43 81 1 Amerriican Cancerr Sociietty MRI: Maiin Diisadvantages New guidelines issued on March 28 th , 2007 Compllexiitty Recommend annual MRI screening for women with a high lifetime ri sk of •• Typiicall conttrrastt enhanced brreastt MRII may conttaiin overr 1500 breast cancer – defined as 20% or more iimages Costt (Mediicare reiimbursementt ratte) June 2008 •• Anallog Mammogrram ~$90 •• Diigiittall Mammogrram ~$140 •• Biillatterrall brreastt ullttrrasound ~$200 •• Biillatterrall MRII > $1,,000 Speciiffiiciitty •• ((tterrttiiarry centterrs)) ~ 90% •• ((communiitty centterrs)) ~ 50% Nucllear Mediiciine / Mollecullar Imagiing IImpactt off Tumor Siize on Mettasttattiic Diisease Sciinttiimammography <10 mm: 5 -year survival = 98% • Tc --99m sesttamiibii apprroved by tthe FDA fforr brreastt iimagiing 30 mm : 5 -year survival = 70% iin 1997 90 Aust. Inst. Health Welfare, Oct 2007 • Severrall llarrge mullttiicentterr sttudiies underrttaken iin llatte 1990s 7700% 6600% Taiillllefferr :: Sem Nucll Med 29::16,, 1999 60 5522% ((2009 pattiientts)) % wiitth 4455% Sensitivity = 85%, specificity = 89% Mettassttattiicc 3333% Sensitivity = 85%, specificity = 89% Diisseasse 30 2200% Brem : J Nucl Med 43:909, 2002 Sensitivity 35 -64% for lesions <1 cm 0 Taillefer : Sem Nucl Med 29:16, 1999 <0.5 0.5 -1.0 1-2 2-3 3-4 4-5 >5 Sensitivity ~55% for masses <1.5 cm Tumorr siize ((cm)) 2 Conventionall Sciintiimammography Small Field of View Gamma Cameras Diigiirad Diillon IInc.. CZT Technollogy Mullttiicrrysttall Mullttiicrrysttall Cadmiium Ziinc Cesiium IIodiide Sodiium IIodiide Tellllurriide ((CZT)) + Phottodiiodes + PMTs Semiiconducttorr Breast Phantom: Comparison between Systems* Cadmium Zinc Telluride (CZT) Detector *Hruska CB, et al. Nucl Med Commun , 2005; 26: 441 -445 Tumor Depth 2.54 cm 1cm • Excellent Intrinsic Resolution = 1.6 mm 3 cm • Excellent Energy Resolution 4.0% • Can be operated at room temp • No dead space – ideal for breast imaging • Expensive – currently limited to small 5 cm field of view detectors • First commercial gamma cameras using MC -NaI NaI CZT MC -CsI CZT developed for nuclear cardiology 3 Energy Resolution - CZT Detector Mollecullar Breast Imagiing – 2009 MBI Prototypes developed at Mayo over last 6 yrs using detectors from Gamma Medica and GE Healthcare Cadmium Zinc Telluride (CZT) gamma camera technology • Expensive – currently limited to small field of view detectors Dual -detector design optimized for breast imaging Anticipated cost ~$400 / study Dual -detector MBI System Can MBI find small breast tumors? How does Molecular Breast Imaging Work? Can MBI find small breast tumors? Patient receives an IV injection of a radiotracer (Tc -99m sestamibi) The tracer preferentially accumulates in cancer cells and is not influenced by breast density The breast is lightly compressed between the 2 MBI gamma cameras, only light pain -free compression is necessary Imaging starts ~5 minutes post injection. Acquire CC and MLO views of each breast for 10 minutes / view Procedure performed by nuclear medicine technologist trained in mammographic positioning techniques 4 Compariison off Screeniing MBII and Vol 191, 1808 -1815 Mammography ~1000 pattiientt scrreeniing sttudy Technology Tumors 5 -10 mm Tumors < 5 mm All Tumors (128 Funded by Susan G Komen Foundattiion in size in size in 88 patients) Comparre MBII and mammogrraphy iin pattiientts wiitth dense breasts at high risk of breast cancer Standard -Camera* 55% No data dense breasts at high risk of breast cancer Prriiorr hiisttorry off brreastt cancerr Single -head MBI 76% 44% 82% Famiilly hiisttorry iin one FDR orr ttwo SDR Dual -head MBI 87% 67% 90% Gaiill lliiffettiime rriisk > 20% *Palmedo et al: EJNM 25:375, 1998 Prriiorr attypiia orr LCIIS Questtiion – iis MBII a viiablle scrreeniing adjjunctt tto mammogrraphy iin pattiientts wiitth dense brreastts? 18 mm 10 mm 8 mm 5 mm 3 mm Results Screening Patient Examples (1) In 958 patients studied, a total of 14 cancers in 12 patients were diagnosed. Rt CC Rt MLO • 8 cancers detected by MBI alone • 1 cancer detected by mammography alone • 2 cancers detected by both MBI and mammography 100 79 % (11 / 14) 71 % (10 / 14) 80 % of 60 Cancers Detected 40 21 % (3 / 14) 20 Digital Screening Mammography (Negative) 0 MMG MBI Combination Molecular Breast Imaging (Positive) Imaging Modality 17 mm IDC with DCIS extension 5 Screening Patient Examples (2) A L R MBI P Digital Screening vs.vs. Mammography SPECT (Negative) SPECT Molecular Breast Imaging Rt MLO (Positive) Parathyroid scan with Tc -99m sestamibi performed 4 weeks prior to MBI study in Screening Patient Example #3 9 mm Ductal Carcinoma In Situ Screening Patient Examples (3) Screening Patient Examples (4) Lt CC Lt MLO Digital Screening Mammography (Negative) Molecular Breast Imaging (Positive) Digital Screening Mammography (Negative) Rt MLO Molecular Breast Imaging (Positive) 9 mm Invasive Ductal Carcinoma 7 mm Tubulolobular Carcinoma 6 Results in 958 Patients with 12 -month Follow -up Molecular Breast Imaging in Patients undergoing Myocardial Perfusion Imaging Sensiittiiviitty:: Allll cancerrs dettectted by any means iin tthe 12 --montth perriiod siince tthe MBII sttudy.. MBIs performed in women presented for myocardial 10 // 14 cancerrs dettectted by MBII perfusion studies, no additional dose needed (sensitivity = 71%) (sensitivity = 71%) Of 158 patients 3 // 14 cancerrs dettectted by mammogrraphy • 3 cancers detected, 1 only detected by MBI (sensitivity = 21%) (sensitivity = 21%) • 1 patient with uptake in papilloma and atypia • 154 patients with negative findings Speciiffiiciitty:: Pattiientts wiitth a negattiive ffollllow --up mammogrram att 1 yearr and Negative screening mammogram no clliiniicall sympttoms att 12 --montths werre assumed tto be diisease ffrree Myocardial perfusion scan and MBI 1 week later Specificity - MBI 93% Recall Rate – 7.5 % Specificity - MBI 93% Recall Rate – 7.5 % Follow -up Dx mmg /US positive, 8 mm IDC/DCIS Speciiffiiciitty -- mammogrraphy 90% Recallll Ratte – 9..2 % IDC/DCIS Breast MRI correlated with MBI MBI - Potential Screening Application MBI - Limitations and Disadvantages MBI has 2 -3 times sensitivity of mammography in the high -risk and dense breast populations False positive findings in some cases of MBI appears to have comparable sensitivity (80%) to that reported for MRI in women at increased risk of fibroadenomas, papillllomas, fat necrosiis. breast cancer American Cancer Society guidelines recommend Uptake of Sestamibi is influenced by hormonal annual MRI if lifetime risk exceeds 20%: would impact changes up to 1.5 million women annually in the U.S. Cost of MBI estimated at ~1/5 th cost of Breast MBI MBI - high radiation dose relative to Currently no clinical systems available mammography - First clinical systems in late 2009 ? 7 Cumulative Cancer Incidence per 100,000 women from annual MBI: Implications for Radiation Exposure to the screening with Mammography or Tc -99m sestamibi starting at age 40 MBI: Implications for Radiation Exposure to the 3500 Technologist from 8 patients / day, 20 mCii / patient 0 3000 0 0 , 0 0 500 1 2500 / e c n 400 e 2000 d i c 2 - 4 mCi Sestamibi n I r Mammogram 3.8 – 6.6 mGy 300 e 1500 MBI c 25 mCi Sestamibi mrem n Tech a Background Radiation C e 200 1000 v i t a l u 100 General Cardiology m 500 NMT u NMT Radiographer C 0 0 40 45 50 55 60 65 70 75 80 Annual Technologist Dose Age (years) MBI – Radiation Dose MBI Dose Reduction 20 mCi Dose 4 mCi Dose Radiation risk to patients / technologists Upper Rt. MLO Upper Rt. MLO MBI with 20 mCi Tc -99m sestamibi = 6.5 mSv Rt. MLO Mammogram is < 1.0 mSv Combined/filtered Dose reduction techniques have been developed to reduce administered dose of Tc -99m sestamibi to 2 -4 mCi - collimator optimization - energy window optimization - noise reduction algorithms - composite image from opposing detectors Lower Rt. MLO Lower Rt. MLO 8 MBI - Future Directions Mollecullar Breastt IImagiing Futturre Devellopmentts – New Radiiopharrmaceuttiicalls Clinical applications Tc --99m Sesttamiibii Tc --99m Bombesiin Screening in high -risk women • Tc --99m V-3 IInttegrriin • Pre -operative staging to exclude multifocal/contralateral Tc --99m Annexiin V cancers Tc --99m Gllucarratte • Neo -adjuvant chemotherapy evaluation Tc --99m EC --gllucosamiine Tc --99m ((V)) --DMSA Tc --99m Viittamiin B12 Alternative radiotracers I-I-123 IIodo --esttrradiioll I-I-123 Metthoxy --viinyllesttrradiioll • Improved detection of lesions < 5 mm I-I-123 Diimetthyll --Tamoxiiffen • Improved detection of DCIS and atypia I-I-123 IIodo --metthoxybenzamiide 9.
Recommended publications
  • Molecular Imaging – Introduction

    Molecular Imaging – Introduction

    MOLECULAR IMAGING – INTRODUCTION Author: Markus Rudin Affiliation: Institute for Biomedical Engineering, University and ETH Zurich, Institute for Pharmacology and Toxicology, University of Zurich, HCI-E488.2, ETH Zurich, CH-8093 Zurich, Switzerland, [email protected] Introduction The primary role of biomedical imaging is in diagnostics, i.e. the characterization of a disease phenotype based on morphological or physiological readouts. Image quality is rated based on two criteria: spatial resolution and contrast-to-noise ratio. Image contrast and thereby information can be enhanced by administration of labels that either enhance the contrast in the image or generate a signal that otherwise would not be detectable. When combining a signal generating moiety (a reporter group) with a target-specific carrier (receptor ligand, enzyme substrate, antibody, oligonucleotide, cell) highly specific information on targeted molecular interactions can be obtained. Such target-specific or molecular imaging approaches raised considerable interest both from a diagnostic and therapeutic point-of-view 1-3, and will become important tools for biomedical researchers. They provide temporo-spatial information on molecular processes in the intact organism, i.e. in the full biological context with all regulatory interactions in place. Molecular imaging techniques will therefore play a role for the validation for systems biological approaches. As for structural and functional imaging a primary application area of molecular imaging will be in diagnostics. Tissue/organ structure and function can be considered a phenotype of a molecular program. Being able to visualize and quantify these molecular processes will therefore provide early information on pathologies, eventually in a pre-morbid state. Molecular information will certainly enhance the accuracy of diagnosis allowing for better therapy planning for the individual patient (personalized medicine).
  • Future of Breast Elastography

    Future of Breast Elastography

    Future of breast elastography Richard Gary Barr1,2 1Department of Radiology, Northeastern Ohio Medical University, Rootstown, OH; 2Southwoods Imaging, Youngstown, OH, USA REVIEW ARTICLE Both strain elastography and shear wave elastography have been shown to have high sensitivity https://doi.org/10.14366/usg.18053 pISSN: 2288-5919 • eISSN: 2288-5943 and specificity for characterizing breast lesions as benign or malignant. Training is important for Ultrasonography 2019;38:93-105 both strain and shear wave elastography. The unique feature of benign lesions measuring smaller on elastography than B-mode imaging and malignant lesions appearing larger on elastography is an important feature for characterization of breast masses. There are several artifacts which can contain diagnostic information or alert to technique problems. Both strain and shear wave elastography continue to have improvements and new techniques will soon be available for Received: September 21, 2018 clinical use that may provide additional diagnostic information. This paper reviews the present Revised: January 4, 2019 Accepted: January 4, 2019 state of breast elastography and discusses future techniques that are not yet in clinical practice. Correspondence to: Richard Gary Barr, MD, PhD, Keywords: Breast; Elasticity imaging techniques; Strain; Shear wave; Strain ratio; Southwoods Imaging, 7623 Market Street, Youngstown, OH 44512, USA Breast neoplasms Tel. +1-330-965-5100 Fax. +1-330-965-5109 E-mail: [email protected] Introduction The use of palpation to determine the stiffness of a lesion has been used since the time of the ancient Greeks and Egyptians [1]. Stiff, non-mobile lesions of the breast have a high probability of being malignant.
  • Understanding Cost & Coverage Issues with Diagnostic Breast Imaging

    Understanding Cost & Coverage Issues with Diagnostic Breast Imaging

    Understanding Cost & Coverage Issues with Diagnostic Breast Imaging JANUARY 2019 The following report represents key findings from The Martec Group’s primary and secondary research efforts. The team was instructed to explore the cost and coverage issue with breast diagnostic imaging in order to equip Susan G. Komen with the information necessary to strategize efforts at the state and federal levels. TABLE OF CONTENTS: I. A Brief Summary of Findings ................................................................................................................... 3 II. Project Background ..................................................................................................................................... 3 III. Study Objectives ........................................................................................................................................... 3 IV. Research Methodology .............................................................................................................................. 3 V. Patient Perspective ...................................................................................................................................... 4 VI. Health/Insurance Professional Perspective ...................................................................................... 5 VII. Cost Analysis .................................................................................................................................................. 6 VIII. Study Conclusions .......................................................................................................................................
  • Breast MRI: New and Abbreviated Protocols

    Breast MRI: New and Abbreviated Protocols

    Breast MRI: New and Abbreviated Protocols Christopher Comstock M.D. Department of Radiology Memorial Sloan-Kettering Cancer Center Topics • What is our goal? • Current status of screening • How do we change screening • Abbreviated Breast MRI (AB-MR) • EA1141 AB-MR Trial • Multiparametric Breast MRI Beyond the scope of this talk! • The debate over screening the benefit of mammography, particularly for women in their forties. What is Our Goal? • Decrease breast cancer mortality • Reduction in the morbidities associated with surgery and chemotherapy • Finding breast cancers at a smaller size and earlier stage leads to a reduction in mortality and the use of less aggressive therapies Reservoir of Breast Cancer Present in 1000 Women Being Screened • Is it 30, 40, 50, 60 or more breast cancers per 1000 women? • Depends on risk of population • Detection level (size and stage) depends on modality and frequency of screening Reservoir of Breast Cancer Present in 1000 Women Being Screened Tomo plus WBUS The Dissemination of Medical Technologies into Clinical Practice • Innovations medical in technology and quality of information are the sole driving force in the acceptance and adoption of new technologies • The dissemination of medical technologies depends on the social, political and ideological context into which they are introduced Much Can Be Learned From the History of Mammography • Despite improvements in technology, mammography languished from 1930s to 1970 – 1930-1950 Stafford L. Warren, Jacob Gershon-Cohen and Raul Leborgne – 1950s Improved techniques, Robert Egan • The production of better data alone did not eliminate the role that economics, authority and ideology played “TO SEE TODAY WITH THE EYES OF TOMORROW” A HISTORY OF SCREENING MAMMOGRAPHY.
  • Breast Elastography – Ultrasound Or Magnetic Resonance

    Breast Elastography – Ultrasound Or Magnetic Resonance

    Medical Policy Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change. *Current Policy Effective Date: 7/1/21 (See policy history boxes for previous effective dates) Title: Breast Elastography – Ultrasound or Magnetic Resonance Description/Background In the United States, about 1 in 8 women will develop invasive breast cancer over the course of her lifetime. In 2020, is it estimated that there will be over 280,000 new cases of invasive breast cancer diagnosed in women and over 2,600 new cases of invasive breast cancer in men.1 Breast cancer is the most common cancer in women worldwide.2 Mammography remains the generally accepted standard diagnostic test for breast cancer screening and diagnosis. The incidence of breast cancer has led to research on new diagnostic imaging techniques for early diagnosis. Elasticity is the property of a substance to be deformed in response to an external force and to resume its original size and shape when the force is removed. In evaluation of superficial tissue such as skin, breast or prostate, manual palpation can distinguish normal tissue from stiffer tissue. Elastography is a noninvasive technique that evaluates the elastic properties, or stiffness of tissues, and its application for diagnosing breast cancer is based on the principle that malignant tissue is less elastic than normal, healthy breast tissue. Elastography has been investigated as an additive technique to increase the specificity of ultrasound and magnetic resonance imaging.
  • Breast Ultrasound Accreditation Program Requirements

    Breast Ultrasound Accreditation Program Requirements

    Breast Ultrasound Accreditation Program Requirements OVERVIEW ........................................................................................................................................................................... 1 MANDATORY ACCREDITATION TIME REQUIREMENTS .......................................................................................................... 2 PERSONNEL QUALIFICATIONS ..................................................................................................................................... 2 INTERPRETING PHYSICIAN .................................................................................................................................................... 2 SONOGRAPHER/TECHNOLOGIST ........................................................................................................................................... 5 EQUIPMENT ......................................................................................................................................................................... 5 QUALITY CONTROL .......................................................................................................................................................... 6 ACCEPTANCE TESTING ......................................................................................................................................................... 6 ANNUAL SURVEY ................................................................................................................................................................
  • Evaluation of Nipple Discharge

    Evaluation of Nipple Discharge

    New 2016 American College of Radiology ACR Appropriateness Criteria® Evaluation of Nipple Discharge Variant 1: Physiologic nipple discharge. Female of any age. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 1 See references [2,4-7]. ☢☢ Digital breast tomosynthesis diagnostic 1 See references [2,4-7]. ☢☢ US breast 1 See references [2,4-7]. O MRI breast without and with IV contrast 1 See references [2,4-7]. O MRI breast without IV contrast 1 See references [2,4-7]. O FDG-PEM 1 See references [2,4-7]. ☢☢☢☢ Sestamibi MBI 1 See references [2,4-7]. ☢☢☢ Ductography 1 See references [2,4-7]. ☢☢ Image-guided core biopsy breast 1 See references [2,4-7]. Varies Image-guided fine needle aspiration breast 1 Varies *Relative Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate Radiation Level Variant 2: Pathologic nipple discharge. Male or female 40 years of age or older. Initial imaging examination. Radiologic Procedure Rating Comments RRL* See references [3,6,8,10,13,14,16,25- Mammography diagnostic 9 29,32,34,42-44,71-73]. ☢☢ See references [3,6,8,10,13,14,16,25- Digital breast tomosynthesis diagnostic 9 29,32,34,42-44,71-73]. ☢☢ US is usually complementary to mammography. It can be an alternative to mammography if the patient had a recent US breast 9 mammogram or is pregnant. See O references [3,5,10,12,13,16,25,30,31,45- 49]. MRI breast without and with IV contrast 1 See references [3,8,23,24,35,46,51-55].
  • Screening Automated Whole Breast Ultrasound

    Screening Automated Whole Breast Ultrasound

    Screening Automated Whole Breast Ultrasound Screening Automated Whole Breast Ultrasound Stanford now offers screening automated whole breast ultrasound (SAWBU) at our Stanford Medicine Cancer Center Palo Alto location. This is an optional test that can be used as a supplement to screening mammography in women with mammographically dense breasts. It can find cancers that cannot be seen on mammograms due to overlap with dense breast tissue. Stanford uses automated whole breast technique, a new method developed for accuracy and efficiency. Who is a candidate for SAWBU What will happen during the How is SAWBU exam is examination? SAWBU examination? different? This is an optional test to supplement You will lie on your back, and gel will Screening automated screening mammography in women be applied to your breast. whole breast ultrasound who: uses sound waves (no radi- A large ultrasound handpiece will be • Undergo routine screening with ation) to create 3D pictures placed on the breast, and the system mammography. of the breast tissue, using will automatically take a “sweep” • Have no current signs or a new automated method that obtains ultrasound images of symptoms of breast cancer. developed for accuracy and the tissue from top to bottom. The • Have mammographically dense efficiency. handpiece will be repositioned to take (heterogeneously or extremely other “sweeps” to include all of the It can find cancers that dense) breasts. breast tissue. cannot be seen on mam- • Are not at “high risk" undergoing mograms alone due to supplemental screening with An exam of both breasts takes less overlap with dense breast breast MRI. Screening ultra- than 20 minutes to obtain.
  • Advanced Ultrasound Technologies for Diagnosis and Therapy

    Advanced Ultrasound Technologies for Diagnosis and Therapy

    Journal of Nuclear Medicine, published on March 1, 2018 as doi:10.2967/jnumed.117.200030 1 Advanced Ultrasound Technologies for Diagnosis and Therapy Anne Rix1, Wiltrud Lederle1, Benjamin Theek1, Twan Lammers1,2, Chrit Moonen3, Georg Schmitz4, Fabian Kiessling1* 1Institute for Experimental Molecular Imaging, RWTH-Aachen University, Aachen, Germany 2Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands 3Imaging Division, University Medical Center Utrecht, Utrecht, The Netherland 4Department of Medical Engineering, Ruhr-University Bochum, Bochum, Germany * Corresponding author: Fabian Kiessling MD, Institute for Experimental Molecular Imaging, University Aachen (RWTH), Forckenbeckstrasse 55, 52074 Aachen, Germany. Phone:+49-241- 8080116; fax:+49-241-8082442; e-mail: [email protected] First author: Anne Rix B.Sc., Institute for Experimental Molecular Imaging, University Aachen (RWTH), Forckenbeckstrasse 55, 52074 Aachen, Germany. Phone:+49-241-8080839; fax:+49- 241-8082442; e-mail: [email protected] Running title Advanced Ultrasound Imaging and Therapy 1 2 ABSTRACT Ultrasound is among the most rapidly advancing imaging techniques. Functional methods such as elastography have been clinically introduced, and tissue characterization is improved by contrast- enhanced scans. Here, novel super-resolution techniques provide unique morphological and functional insights into tissue vascularisation. Functional analyses are complemented with molecular ultrasound imaging, to visualize markers of inflammation and angiogenesis. The full potential of diagnostic ultrasound may become apparent by integrating these multiple imaging features in radiomics approaches. Emerging interest in ultrasound also results from its therapeutic potential. Various applications on tumor ablation with high intensity focused ultrasound (HIFU) are clinically evaluated and its performance strongly benefits from the integration into Magnetic Resonance Imaging (MRI).
  • Evaluation of the Quantitative Accuracy of a Commercially-Available Positron Emission Mammography Scanner

    Evaluation of the Quantitative Accuracy of a Commercially-Available Positron Emission Mammography Scanner

    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 8-2010 EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY-AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER Adam Springer Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Diagnosis Commons, Equipment and Supplies Commons, and the Other Medical Sciences Commons Recommended Citation Springer, Adam, "EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY-AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER" (2010). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 64. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/64 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY- AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER
  • Commercial Reimbursement and Utilization for Invenia ABUS (Automated Breast Ultrasound)

    Commercial Reimbursement and Utilization for Invenia ABUS (Automated Breast Ultrasound)

    Commercial Reimbursement and Utilization for Invenia ABUS (Automated Breast Ultrasound) Background interpreting physician, referring physician/Health Care Provider (HCP), and patient.6 Specifically, the MQSA encourages education More than one-half of women younger than 50 years old and and outreach to patients from medical/scientific organizations, approximately one-third of women 50 years and older have industry, and interpreting physicians. In addition, outreach to dense breasts in the US.1 Higher breast density is associated referring physicians is encouraged from professional organizations with decreased mammographic sensitivity and specificity and and Continuing Medical Education (CME) providers.6 increased breast cancer risk.2 Due to the shortcomings of mammography in this population of women, an individualized Despite widely available options for additional screening and multimodal screening approach is recommended to improve the legislation mandating density inform, uptake and adoption of early detection of breast cancer. No clinical guidelines explicitly supplemental screening has lagged. In addition to knowledge recommend use of supplemental breast cancer screening on gaps, one study identified reimbursement uncertainties (e.g. women with dense breasts,3 but as of March 2018, 33 states have billing, coding and coverage) as a key factor for slow uptake. In enacted legislation requiring that breast density, in addition to 2015, the CPT® codebook was updated to include two new codes mammography results, be reported to women undergoing such for breast ultrasound, CPT 76641 and 76642, for complete and procedures; additional states have introduced or are currently limited exams, respectively.7 These codes replaced CPT 76645. working on legislation.4 Most states require specific density The new and old codes alike do not differentiate the technology inform language distinguishing dense (i.e., BI-RADS® C and D) used to perform an exam (handheld vs.
  • Molecular Imaging Tutorial

    Molecular Imaging Tutorial

    This tutorial will define what is currently considered molecular imaging. It will provide history and an overview, discuss the goals and the advantages of molecular imaging. It will clarify what is and is not molecular imaging, and give examples of different imaging case studies. It will also discuss MRI, Optical Imaging, SPECT and PET imaging, and how they relate to molecular imaging. Molecular Imaging: Definition, Overview and Goals • Definition as published in Eur J Nucl Med: Molecular imaging has its roots in nuclear medicine and in many ways is a direct extension of this discipline. Nuclear Medicine has always focused on patient management through the use of injected radiolabeled tracers in conjunction with imaging technology. • Definition as published in Genes & Dev: Molecular imaging is the visual representation, characterization, and quantification of biological processes at the cellular and subcellular levels within intact living organisms. The images obtained reflect cellular and molecular pathways and in vivo mechanisms of disease present within the natural physiological environment. • Definition according to the American College of Radiology: Molecular imaging is the spatially localized and/or temporally resolved sensing of molecular and cellular processes in vivo. Overview of Molecular Imaging • Development of the first microscope in the late sixteenth century led to a keen interest in observations of structure of tissues and organs. This interest in organ structure and function has driven advances in biology ever since. • Molecular imaging originated from the field of radiopharmacology due to the need to better understand the fundamental molecular pathways inside organisms in a noninvasive manner. Molecular imaging unites molecular biology and in vivo imaging and enables the visualization of cellular function and the follow-up of the molecular process in living organisms without perturbing them.